Every 10-Q that MiMedx Group, Inc (MDXG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDXG filings page.
MiMedx Group, Inc. (MDXG) reported third-quarter 2026 net sales of $62.3 million, down 45.2% year over year, and a net loss of $8.7 million versus $16.7 million income a year earlier. Surgical sales rose 9.1% to $40.0 million; Wound sales fell 71.0% to $22.3 million, principally due to Medicare reimbursement changes effective January 1, 2026. Gross margin was 79.8%, versus 83.5%.
Nine-month operating cash flow was a $4.2 million use, versus $49.0 million provided a year earlier; cash was $120.8 million as of September 30, 2026. MiMedx repaid $17.3 million of term debt but was not in compliance with a financial covenant as of that date, constituting an Event of Default. Lenders waived the default; revolver borrowing is barred until compliance returns.
The pending Sanara acquisition has an enterprise value of approximately $350 million. Under the agreement, each outstanding Sanara share would convert into a right to receive $33.00 cash and 0.4735 MiMedx shares, subject to adjustments. The FTC's October 15, 2026 Second Request extends the HSR waiting period. An October 2026 patent license provides $25.0 million in five annual $5.0 million installments; the first was paid in the fourth quarter of 2026. A court vacated FDA determinations on AXIOFILL and remanded them for further consideration.
MiMedx Group reported sharply weaker results for the quarter ended June 30, 2026 and disclosed a pending acquisition. Net sales were $64,362 thousand, down 34.7% from 2025, as Wound revenue fell 61.1% to $25,065 thousand following Medicare reimbursement changes; Surgical revenue rose 15.1% to $39,297 thousand.
Gross margin narrowed to 69.0% from 81.1%. The company posted a quarterly net loss of $14,840 thousand (basic and diluted loss per share $0.10) versus prior-year net income of $9,618 thousand, and a six‑month net loss of $25,700 thousand. Cash and cash equivalents were $135,839 thousand, with $8,136 thousand of cash used in operating activities year to date, $17,250 thousand outstanding on the term loan at a 6.0% rate, and no revolver borrowings.
MiMedx repurchased 3,464,399 shares for about $12.7 million under a $100 million Share Repurchase Plan. After quarter‑end, it agreed to acquire Sanara MedTech for $35.00 per share, valuing Sanara at approximately $350 million, using roughly $302 million in cash and 4,400,000 MiMedx shares, backed by a committed $300.0 million six‑year Hayfin term loan at Term SOFR plus 6.25% and an announced prepayment of the remaining $17.3 million Citizens term loan.
MiMedx Group reported Q1 2026 net sales of $59.0 million, down 33.1% from $88.2 million a year earlier, and recorded a net loss of $10.9 million versus prior-year net income of $7.0 million. Wound segment sales fell 59.7% to $22.6 million following January 1, 2026 Medicare reimbursement changes for skin substitutes, while Surgical sales grew 13.2% to $36.4 million.
Gross margin compressed to 70.6% from 81.2%, reflecting lower Wound pricing, an unfavorable mix and higher costs. The company ended the quarter with $159.8 million in cash and equivalents, $44.6 million in current liabilities, and $17.6 million of term debt outstanding, leaving its $75.0 million revolver undrawn.
Operating cash flow was $1.9 million, aided by strong receivables collections. MiMedx invested $5.0 million upfront for exclusive U.S. rights to RegenKit Wound Gel and noted a remaining $1.3 million profit-share obligation to TELA Bio. After quarter-end it announced a cost reduction initiative, including a workforce reduction of about 15% and expected one-time charges of roughly $4 million in Q2 2026.
MiMedx Group (MDXG) reported a strong Q3 2025. Net sales rose to $113.7 million, up 35% year over year, driven by newer Wound products CELERA and EMERGE and broad-based Surgical strength. Wound sales reached $77.1 million (up 40%), and Surgical sales were $36.6 million (up 26%). Gross margin improved to 83.5% from 81.8% on favorable production variances and mix.
GAAP net income was $16.7 million with diluted EPS of $0.11, versus $0.05 a year ago, as operating income doubled to $22.2 million. Cash and equivalents increased to $142.1 million, supported by $49.0 million in operating cash flow year to date. The company ended the quarter with $18.3 million of term debt at a 6.5% rate and no borrowings on its revolver. Management highlighted potential reimbursement changes starting January 1, 2026, with CMS proposing a fixed price of $125.38 per square centimeter for skin substitutes across settings; final rules are expected this year.